Comparative Analysis of Transplacental SARS-CoV-2 Antibody Transfer in Pregnancy Phenotypes With Pre-eclampsia and/or Small-for-gestational-age Infants.

Publication date: Feb 01, 2025

We analyzed paired maternal and cord samples for anti-spike protein antibody levels from pregnant individuals who received at least 2 doses of an mRNA COVID-19 vaccine before delivery and who had diagnoses consistent with placental dysfunction including pre-eclampsia and/or small-for-gestational-age infants. Our findings reveal similar median maternal and cord antibody levels across all groups despite the presence of these pregnancy complications.

Open Access PDF

Concepts	Keywords
Covid	Adult
Mrna	Antibodies, Viral
Pregnant	Antibodies, Viral
Vaccine	COVID-19
	COVID-19 Vaccines
	COVID-19 Vaccines
	Female
	Fetal Blood
	Humans
	Immunity, Maternally-Acquired
	Infant, Newborn
	Phenotype
	Placenta
	Pre-Eclampsia
	Pregnancy
	Pregnancy Complications, Infectious
	SARS-CoV-2
	Spike Glycoprotein, Coronavirus
	Spike Glycoprotein, Coronavirus
	spike protein, SARS-CoV-2

Semantics

Type	Source	Name
disease	MESH	Pre-eclampsia
disease	IDO	protein
disease	MESH	pregnancy complications
drug	DRUGBANK	Coenzyme M
disease	MESH	COVID 19
disease	MESH	infection
disease	MESH	morbidity
disease	MESH	stillbirth
disease	MESH	preterm birth
disease	MESH	complications
disease	MESH	hypertension
disease	MESH	proteinuria
disease	MESH	placental insufficiency
disease	IDO	pathogen
disease	IDO	blood
disease	MESH	HELLP syndrome
disease	MESH	eclampsia
disease	MESH	Infant Small for Gestational Age
disease	MESH	Pregnancy Complications Infectious

Original Article

(Visited 2 times, 1 visits today)